VIM and pancreatic neoplasm: As a proof of principle using previously identified EMTCTCs1, 2, 39, we were able to rapidly screen these cells for mesenchymal stem cell markers (CD34 and Vimentin)27, 34, motility markers (CXCR4 and Vimentin)27, 28, 30, 34, and inflammatory markers (PD-L1 and PD1)40 to characterize the expression profiles and typing of EMTCTCs found in pancreatic cancer patients.